Synthesis and degradation of collagen is an essential component of wound healing . In most persons, this deposition of collagen results in the formation of a fine line scar which restores much of the tensile strength to the injured tissue and is cosmetically acceptable . However, in certain individuals, the result of wound healing is the excessive accumulation of collagen, resulting in a hypertrophic scar or keloid . The precise origin of this abnormal collagen deposition is unknown, but recent studies have begun to identify potential mechanisms for these disfiguring and painful lesions . This article will review the clinical and laboratory findings pertinent to understanding the origin and treatment of excessive scarring . (WOUND REP REG 1995 ;3 :6-94) 
Growth, regeneration, and repair are a continuum of processes which form new tissue . During human embryogenesis and fetal wound healing, dividing layers of cells coalesce to form discrete organs and tissues. Tissues formed in this manner increase in size while maintaining their unique architecture . In adults, the liver and muscle retain this ability to increase tissue mass and regenerate through cell division . Those tissues formed by regeneration are indistinguishable from adjacent normal tissue . In contrast, healing of most tissue defects is by repair and is easily identifiable by the formation of scar .
Normal wound healing comprises a mixture of regeneration and repair and is a highly regulated cascade of events . Cells respond to the disruption of their environment by the release of mediators which stimulate chemotaxis, cellular proliferation, and the deposition of extracellular matrix proteins . Typically in Sometimes, the cellular processes contributing to repair become unregulated. A potential result is excess matrix synthesis, which results in excessive scarring . The adult wound that heals with excessive scar and the fetal wound that heals with no scar represent extremes of common fundamental processes of cell proliferation and extracellular matrix production and may reflect differences in regulatory function .
Hypertrophic scars and keloids have likely been present as long as human beings have been wounded. Abnormal scarring is mentioned in the Smith Papyrus of 2500 and 3000 B.C .' Keloid formation is depicted in a 13th century Yoruba sculpture from West Nigeria. In 1816, Alibert first proposed the word keloid to differentiate these scar excrescences from cancerous tumors . ' The Greek word khele, meaning crab claw, is the root of the word describing the small claw-like projections of severe scarring extending beyond the original wound border into normal tissue .' Figure 1 Earlobe keloid arising along the helical rim from earring puncture . Note the earlobe puncture site uninvolved by keloid .
CLINICAL PRESENTATION
Hypertrophic scars and keloids occur in 5% to 15% of wounds, and present a 5-to 15-fold higher risk to dark-skinned people .`The clinical distinction is that hypertrophic scars remain within the borders of the original scar, whereas keloids extend beyond the original scar margins.' Certain populations are more prone to excessive scarring than others . Dark-skinned patients between the ages of 2 and 40 years have an increased risk of the development of hypertrophic scars or keloids. However, patients in whom keloids or hypertrophic scars form during their childhood or teenage years may not exhibit this tendency later in life ." Regional susceptibility to abnormal scars is recognized . Wounds crossing skin tension lines, in thick skin or in characteristic locations such as the presternal and deltoid regions of the trunk and earlobes, are prone to abnormal scarring (Figures 1 and 2) . Some locations such as genitalia, eyelids, palms of the hand, and soles of the feet almost never develop abnormal scars. ' Keloid formation occurs mainly in parts of the body where the concentration of melanocytes is greatest, as well as during times of physiologic hyperactivity in the pituitary such as during puberty and pregnancy.lo Keloids are not limited to the skin and, though uncommon, have been reported on the cornea ." Many LADIN GARNER, smITH Figure 2 Hypertrophic scar formation after burns is most marked on the dorsal aspect of the second and third web spaces in this patient.
authors have recognized a familial tendency in keloid formation."T he time interval between injury and abnormal scar formation is variable . Hypertrophic scars generally begin to develop in the weeks after injury, whereas keloids may develop up to 1 year later. These scars are raised, nodular, pruritic, and sometimes painful. Patients with hypertrophic scar may seek a surgeon's attention for reasons such as local pain, itching, mass effect, chronic superficial skin breakdown, or unsightly appearance . In addition, function may be compromised when hypertrophic scarring occurs across a joint, creating flexion contractures . In patients with keloid, unsightly appearance, pruritus, or continued growth may result in a consultation for plastic surgery. Hypertrophic scars appear hyperemic, and Ehrlich and Kelly have documented elevated blood flow in hypertrophic scars as long as a year after healing." Deitch et al . 16 noted that wounds with prolonged initial healing have a much greater propensity to form hypertrophic scar . This finding suggests a relationship in which a disordered repair scheme results in disordered healing. Hypertrophic scars may subside, whereas keloids generally do not. ' high mesenchymal density, and thickened epidermal layer. Collagen fibers are organized in swirls . Few macrophages are present, whereas some lymphocytes and eosinophils are found .'°Histologic criteria characteristic of keloids, not hypertrophic scar, include the presence of broad eosinophilic refractive hyaline-like collagen fibers .' Mucinous ground substance is abundant in keloids, but fibroblast density is less than that in hypertrophic scars. Scanning electron microscopy shows morphologic differences. The collagen weave in hypertrophic scars is different from that seen in normal skin or mature scar . Collagen bundles are flatter and less clearly demarcated, whereas fibers are loosely arrayed in a wavy pattern, fragmented, and shortened. The ultrastructure ofkeloids show even less organization . Their fibers are larger and more irregular, and their interfibrillar distance is less than that seen in hypertrophic scars. Discrete collagen bundles are virtually nonexistent, and fibers are randomly oriented to the epithelial surface. The collagen nodule has been identified as a distinguishing structural unit between hypertrophic scar and keloid ." The nodule, which is absent from mature scars, contains a high density of fibroblasts and unidirectional collagen fibrils aligned in a highly stressed orientation. Microvessels encircle the main body of the nodule as a knot ; few appear within it.
Most microvessels in keloids and hypertrophic scars are partially or fully occluded, apparently owing to an excess of endothelial cells. Perivascular satellite cells, some of which share a similar structure to myofibroblasts, are also present.'9 PATHOGENESIS The cause of excessive scarring is multifactorial, and various causal theories of heredity, ischemia, mechani-WOUND REPAIR AND REGENERATION JANUARY-MARCH 1995 cal stretch, and hormonal, immune, or inflammatory mechanisms have been suggested.' Because the cause ofabnormal scars is multifactorial, emphasis should be placed on understanding the final common cellular pathways which are manifest as a prolongation of the proliferative phase of wound healing. The clinical association of delayed wound healing and abnormal scar formation suggests that disruption of the normal healing cascade may result in abnormal wound healing.
The following section § focus on specific alterations in cellular biochemistry, molecular biology including growth factors, and immunology that have been noted in keloids and hypertrophic scar .
BIOCHEMISTRY
Biochemical differences have been found in studies of abnormal scars, mature scars, and normal skin ( Table  1) . Collagen synthesis, as measured by prolyl hydroxylase activity, is significantly higher in keloids than in hypertrophic scars, and both are higher than in normal skin ." Ala-t, -okko, Rintala, and Savolainen" showed keloid prolyl hydroxylase activity to be significantly greater than that found in normal control skin. Collagen synthesis in keloids is approximately 20 times greater than that in normal unscarred skin and three times greater than that found in hypertrophic scar." Normal scar and skin adjacent to normal scar do not have significantly different rates of collagen synthesis . Craig, Schofield, and Jackson 21, 21 found the rate of collagen synthesis in keloids and hypertrophic scars fall to normal levels 2 to 3 years after injury . Cohen2 ' and Harris 2' and their associates noted increased soluble collagen in keloid scars, suggesting increased collagen synthesis, increased degradation, or decreased crosslinking. Knapp, Daniels, and Kaplan2' observed that normal skin, like mature scar, had proportionally greater content of highly cross-linked collagen than that found in keloids. This finding is not due to differences in lysyl oxidase, the enzyme crucial to cross-linking. Although these results are somewhat conflicting, these studies suggest intrinsic increases in collagen synthesis by scar tissues. The differences may be due to the fact that the samples were not all normalized to cell number and were obtained at different time periods after the initial wound. Garner et al .28 studied ascorbate-induced collagen synthesis by hypertrophic scar and normal dermal fibroblasts, matched by patient and derived from clinically active scars. The hypertrophic scar fibroblasts showed a significant increase in collagen synthesis. The findings of immature matrix suggest that keloids have a WOUND REPAIR AND REGENERATION VOL. 3, NO. 1 prolongation of the fibroplasia phase of wound healing and do not progress normally into the subsequent remodeling phase.
Collagenase activity in keloids, hypertrophic scars, and mature scars has been shown to be greater than that found in normal skin . Keloids show 14 times as much collagenase activity as does normal scar, whereas hypertrophic scar showed four times as much enzyme activity. 2s,3o I n spite of increased potential degradative activity, a disproportionate increase in collagen synthesis might lead to net deposition of extracellular matrix and scar. Diegelmann, Bryant, and Cohen" described the presence of the plasma proteins alpha I antitrypsin and alpha II macroglobulin within the interstitial space of abnormal scars. These serum proteinase inhibitors are thought to inhibit degradation of connective tissue . Linares and Larson12 have shown that collagen fibers coated with chondroitin-4-sulfate are resistant to digestion by collagenase. The overabundance of chondroitin-4-sulfate shown by Kischer33 and Shetlar34 and their associates may contribute to the net deposition of collagen in both keloids and hypertrophic scars.
Fibronectin is an important extracellular matrix molecule prevalent in early wound healing which later assumes a lesser role as fibroplasia supervenes . Keloid fibroblasts accumulate more cytoplasmic and cell surface-associated fibronectin than do normal fibroblasts. Babu, Diegelmann, and Oliver 31 observed a onefold to fourfold increase in the rate offibronectin biosynthesis relative to that in normal cells, which could be accounted for at the transcriptional level. Net accumulation of fibronectin in these fibroblasts may cause elevated fibronectin levels within keloid lesions. The fibronectin receptor (the a5R1 integrin heterodimer) was also noted to be increased within the keloid cells relative to normal cells. The combination of increased synthesis of fibronectin and increased expression of its receptor suggests lack ofan inhibitory signal within the temporal sequence of wound healing and may contribute to the continued generation of extracellular matrix by means of integrin signaling to mesenchymal cells. Hyaluronic acid, an important constituent of the extracellular matrix, accumulates in fibrotic disorders and is catabolized less effectively by hypertrophic scar fibroblasts than by normal controls ." This situation may be the result of a global increase in protein synthesis. The implications of an increase in hyaluronic acid and fibronectin is unclear because the extracellular matrix in fetal wounds is also rich in hyaluronic acid and fibronectin, with type III collagen being more abundant than type I collagen, yet those wounds ultimately heal with scant matrix deposition . a pathologic process in which extracellular matrix fails to mature and achieve normal stability. They conclude that the collagenous extracellular matrix in keloids fails to mature, restore its normal collagen composition, and attain stability through cross-linking as in normal skin.
Recent studies have begun to investigate gene expression in conditions of excessive scarring (Table 2) . Cultured fibroblasts from keloids studied by Uitto et al." compared site-matched skin fibroblasts of healthy age-matched patients . They noted that type I collagen gene expression was enhanced in keloid fibroblast cultures compared with controls . In addition, they noted differences in the ratio of type I to type III procollagen messenger RNAs. Keloid fibroblasts expressed these mRNAs in a 22 :1 ratio (compared to a 6 :1 ratio in controls) as a result of increased type I procollagen expression without alteration of type III procollagen mRNA expression . They concluded that the expression of type I procollagen may be selectively enhanced in keloid fibroblast cultures. The 22 : 1 ratio of type I/type III procollagen mRNA species does not correlate to the subsequent protein production, which may suggest posttranscriptional alterations ofthe type I procollagen mRNA or an increase in type I collagenolysis .
Uitto and associates further assessed type I procollagen gene copy number and found no evidence of gene amplification, therefore suggesting that the increase in type I procollagen mRNA occurs at the transcriptional level." Friedman et al." also studied procollagen gene 'IO LADIN, GARNER, SMITH expression in hypertrophic scar-cultured fibroblasts, noting increased amounts of collagen I mRNA and similarly high transcription rates of that gene in both fibroblast types. It is noteworthy that the procollagen type I/type III mRNA ratio found in keloids was much higher than that in hypertrophic scars. The authors speculated that this difference is due to posttranscriptional control of procollagen I mRNA in hypertrophic scar but not in keloids." Ala-Kokko, Rintala, and Savolainen" also correlated procollagen production to expression of type I and type III procollagen mRNAs but did not detect overexpression of type I and type III procollagen mRNA compared with controls . It is noteworthy that the experiments of Ala-Kokko and associates were carried out in white patients whose keloid fibroblasts may produce less collagen . The age of the lesions studied is also an important factor. AlaKokko and associates also noted expression of type V procollagen mRNA as well ."
Recently, Peltonen et al." were able to spatially localize gene expression within keloids using in situ hybridization techniques. Type I procollagen gene expression was detected along the expanding border of the keloid lesion . The central portion of the lesions characterized by thick coarse collagen bundles did not show active type I procollagen gene expression . Further within keloid lesions, numerous small blood vessels were often surrounded by fibroblasts actively expressing type I procollagen genes. Localization of type III procollagen showed minimal labeling, suggesting heterogeneity of expression of this gene within keloid lesions . The authors speculated that type III procollagen expression may be a transient phenomena during the temporal development of a keloid lesion . Lee" also detected type I and III but not type IV procollagen gene expression in some fibroblasts from keloid tissue by in situ hybridization and speculated that clonal subpopulations are largely responsible for procollagen production. Sollberg, Peltonen, and Uitto" also noted that type VI procollagen mRNA was found localized along blood vessels similar to type I collagen mRNA but its distribution differed in that papillary dermis also actively expressed the type VI procollagen gene, an area devoid of type I collagen gene expression . Type VI collagen has been suggested to play a role in the organization of the extracellular matrix . These results point out the heterogeneity of gene expression within the temporal and topographic domains of an evolving keloid lesion .
Sollberg, Peltonen, and Uitto" noted the proximity of areas of active procollagen gene expression to blood vessels and suggested the possibility that vascular WOUND REPAIR AND REGENERATION JANUARY-MARCH 1995 damage may be one ofthe early events leading to keloid formation . They colocalized type I procollagen mRNA with factor-8 surface antigen expression . These findings indicated that endothelium is capable of expressing type I procollagen genes and that the endothelial cells may contribute to the fibrotic keloid. Additional insight into keloid cells has been derived from keloid cell cultures . Fibroblasts from keloids were noted to show similar growth kinetics to those found in normal skin and normal scar .42,43 However, Russell and Witt43 found that keloid cells were less demanding than normal cells with regard to serum and growth factor requirements and grew to higher densities." They postulated that this reduced growth factor requirement could explain the exuberant growth of keloid into tumorlike masses . Harper45 showed additional in vitro differences in keloid fibroblast lines when contrasted to normal fibroblasts . He noted that the in vitro life span of a keloid fibroblast was 31% shorter than that in normal controls. In his studies, keloid fibroblasts reached a lower cell density than did their normal counterparts . These studies did not stratify keloids into age or region . Indeed, fibroblasts isolated from different levels of the dermis, from the leading edge versus the center, or from early keloids versus late keloids could exhibit different growth properties and culture. The same observations may also hold for hypertrophic scar fibroblasts. Bertolami, Berg, and Messadi36 observed altered growth kinetics in hypertrophic scar fibroblasts, noting a 69-hour doubling time compared with 40 hours for control normal fibroblasts.
GROWTH FACTORS
The role ofgrowth factors in the formation of abnormal scar remains undetermined . Growth factors may profoundly influence multiple pathways involved in cell proliferation, extracellular matrix production, and degradation. Peltonen et al. 39 showed the presence of transforming growth factor-R1 (TGF -R1) protein and messenger RNA in areas of keloid activity expressing type I and type VI procollagen genes (Figure 3) . They speculated that TGF-R1 gene expression by neovascular endothelial cells may activate adjacent fibroblasts to express additional TGF -R, as well as enhance procollagen gene expression .
An altered cellular response to growth factors has been used to define fibroblast phenotypes within hypertrophic scars." Hypertrophic scar-derived fi broblasts showed decreased proliferation in response to epidermal growth factor and fetal bovine serum but not to tumor necrosis factor alpha or platelet-derived growth factor . Although normal dermal fibroblasts responded to TGF-ß with a significant elevation of collagen synthesis, the elevated rate of collagen synthesis by hypertrophic scar fibroblasts was not increased further by TGF-ß l stimulation.
Tan and Peltonen" noted a decrease in collagen synthesis as measured as hydroxy/proline synthesis by keloid fibroblast cultures that had endothelial cell growth factor and heparin added to the cultures. This inhibition was noted to occur at the transcription level. Tan et al. 47 also studied regulation of collagen and proteoglycan expression in keloid fibroblasts in vitro and noted that fibroblast growth factor treatment produced similar responses in keloids and normal dermal fibroblast control cells. Interferon (IFN) is a factor with potential therapeutic benefit for excessive scars. Preliminary data from Sahara et al.4a show IFN-0t2ß mediated suppression of scar fibroblast contraction of collagen gels in vitro. Treatment with this agent has also been shown to normalize keloid collagen, glycosaminoglycan, and collagenase production in vitro." IFN-y also has been shown to decrease cell replication and alpha smooth muscle actin expression in hypertrophic scar fibroblasts in vitro .5°T redget et al." noted IFN-a2ß mediated suppression of types I and III procollagen mRNA and protein production by hypertrophic scar fibroblasts in vitro .
IMMUNOLOGY AND GENETICS
Alterations in immune cells and immunologic function have been suggested as causes for excessive scarring. Keloids may be the result of an immune reaction to skin antigens, sebum, melanin, blood products, or foreign bodies .' Differences in immunoglobulin levels have been shown within keloid scars. 52 Inflammatory cells found within abnormal scar may play important regulatory roles in the fibrogenic process." In particular, mast cells may play a regulatory role in abnormal scars and have been found interspersed along dermal collagen bundles in keloids."," Histamine levels are increased in keloid tissue, which may enhance the formation of collagen. Histamine is also a competitive inhibitor of lysyl oxidase, which can explain the abnormal cross-linkage formation shown in collagen and the increased amounts of soluble collagen in keloids. 26 Castagnoli et al. hypertrophic scar formation. It is noteworthy that fibroblasts and keratinocytes were observed to express class II antigens in hypertrophic scars, but whether they are involved in antigen presentation is a point of speculation. The T-cell population may play an important role in pathogenesis of abnormal scars because persistent perivascular lymphocytes have been seen in abnormal scars associated with increased collagen deposition ." Conversely, mice depleted of T-cells show depressed wound healing ability as assessed by bone breaking strength and collagen synthesis." McCauley et al." established differences in cytokine production by peripheral blood mononuclear cells present in keloid versus control patients. They suggested that an altered Figure 4 Hypertrophic scarring from burns treated with a combination of compressive garments and silicone gel placed in the dorsal web spaces (same patient as seen in Figure 2 ) .
immunoregulation by inflammatory cells rather than primary fibroblast alterations play a significant role in keloid formation.
A genetic predisposition for keloid formation has been recognized, particularly in individuals with multiple lesions, with both autosomal dominant and recessive modes of inheritance reported . 12, 13 The prevalence of several HLA-B and HLA-D loci have been shown at increased levels in patients with keloid" The human leukocyte antigen-DR beta 16 allogenotype has been associated with a 12-fold increased risk for hypertrophic scar formation.61 THERAPY Optimal therapy for excessive scarring has yet to be established. Treatment is empiric, and all modalities are plagued by high recurrence rates, especially in patients with keloid . Current therapy for keloids consists of surgical excision or nonsurgical treatment including radiotherapy and corticosteroid injection. This subject was recently reviewed by Lawrence,' who compared relative efficiencies of the various treatments for keloids. DNA analysis has been used to predict clinical behavior of soft tissue tumors,62 and aneuploid keloids have been noted to have a greater propensity for recurrence .63 Optimal treatment of keloids may be guided by recurrence potential, with more modalities combined for the most difficult lesions.
Treatment for hypertrophic scars similarly involves surgical excision and nonsurgical therapy. Surgical WOUND REPAIR AND REGENERATION JANUARY-MARCH 1995 treatment focuses on reduction of inflammation through early wound closure and on alteration of biochemical forces on the scar through interposition of unscarred skin along tension lines. Among nonsurgical therapies for excessive scars, use of topical silicone," compression therapy," and steroid injections" are of documented benefit (Figure 4) .
The abundance of empiric treatment modalities for excessive scarring attest to the lack of understanding of the pathogenesis of this clinical condition. Treatment strategies directed toward specific alterations in the keloid or hypertrophic scar cell biology will offer the best choice for therapeutic efficacy . For example, blockade of a growth factor with known matrixstimulating properties such as TGF-ß would reduce accumulation of scar tissue . Shah, Foreman, and Ferguson" recently showed that scar formation in normal incisional murine wounds could be limited by antibodies blocking TGF-ß ." There have also been promising trials with IFN in the treatment ofexcessive scar . Uncontrolled trials with the use of IFN-y in the treatment of hypertrophic scarrings' and IFN-(x,, treatment of keloids4' suggest beneficial effects on resolution of these lesions. A small controlled trial of keloid treatment with intralesional injection of IFN-y showed significant reduction in lesion height ." IFN-y also was effective in reducing symptoms and scar size in patients with hypertrophic scar ."
At the present time, no simple cure exists for excessive scarring. It is also difficult to postulate a discrete mechanism responsible for this type of scar formation. Recent advances in molecular biology and biochemistry have provided some detailed descriptive information but have not provided a unifying hypothesis . Overall, hypertrophic scarring seems to be the result of disordered normal healing, a process caused by intrinsically normal cells reacting to exogenous stimuli such as prolonged inflammation or biochemical force. Keloids, on the other hand, may arise in the absence of significant exogenous stimuli and, as such, may be considered to have some endogenous tendency toward excessive scar formation. In both cases, a multifactorial origin is likely . It seems reasonable to prevent prolonged exogenous stimulation of a healing wound and to treat excessive scar formation with combined modalities . Specific endogenous factors driving keloid scar formation may be identified, and specific pharmacotherapy can then be designed to limit those processes. These therapies will ultimately promote degradation or limit production of extracellular matrix within the scar. Treatment strategies targeting specific growth factor receptors or matrix genes may ultimately
